Cargando…

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA; n = 75)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metzger-Filho, Otto, Collier, Katharine, Asad, Sarah, Ansell, Peter J., Watson, Mark, Bae, Junu, Cherian, Mathew, O’Shaughnessy, Joyce, Untch, Michael, Rugo, Hope S., Huober, Jens B., Golshan, Mehra, Sikov, William M., von Minckwitz, Gunter, Rastogi, Priya, Li, Lang, Cheng, Lijun, Maag, David, Wolmark, Norman, Denkert, Carsten, Symmans, W. Fraser, Geyer, Charles E., Loibl, Sibylle, Stover, Daniel G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586340/ https://www.ncbi.nlm.nih.gov/pubmed/34764307 http://dx.doi.org/10.1038/s41523-021-00349-y

Ejemplares similares

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
por: Denkert, Carsten, et al.
Publicado: (2013)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
por: Sinn, Bruno Valentin, et al.
Publicado: (2019)

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
por: Conte, PierFranco, et al.
Publicado: (2020)

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials
por: von Waldenfels, Gabriel, et al.
Publicado: (2018)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
por: Denkert, Carsten, et al.
Publicado: (2023)

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
por: Witzel, Isabell, et al.
Publicado: (2019)

Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents
por: Untch, Michael, et al.
Publicado: (2009)

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
por: Untch, Michael, et al.
Publicado: (2021)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
por: Laakmann, Elena, et al.
Publicado: (2019)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
por: Loibl, Sibylle, et al.
Publicado: (2011)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
por: Witzel, I, et al.
Publicado: (2012)

Cómo construir un huerto vertical : 20 proyectos para minijardines comestibles /
por: Maag, Sibylle
Publicado: (2019)

Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations
por: Untch, Michael, et al.
Publicado: (2023)

The truth about economizing for college: shrinking the college tab
por: O'Shaughnessy, Lynn, et al.
Publicado: (2011)

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes
por: Darb-Esfahani, Silvia, et al.
Publicado: (2014)

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
por: Gerber, Bernd, et al.
Publicado: (2022)

A multidisciplinary approach to optimizing care of patients treated with alpelisib
por: Rugo, Hope S., et al.
Publicado: (2021)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
por: Stevic, Ines, et al.
Publicado: (2018)

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
por: Carey, Lisa A., et al.
Publicado: (2022)

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
por: Loibl, Sibylle, et al.
Publicado: (2008)

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
por: Schneeweiss, Andreas, et al.
Publicado: (2019)

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2009)

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer
por: Wenners, Antonia Sophie, et al.
Publicado: (2012)

Move to strike
por: O'Shaughnessy, Perri
Publicado: (2000)

Obstruction of justice
por: O'Shaughnessy, Perri
Publicado: (1997)

Marketing competitivo : un enfoque estratégico /
por: O'Shaughnessy, John
Publicado: (1991)

¿Por qué compra la gente?
por: O'shaughnessy, Jhon
Publicado: (1989)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007)

Business Organization (RLE: Organizations)
por: O'Shaughnessy, John
Publicado: (2013)

Breach of promise /
por: O'Shaughnessy, Perri
Publicado: (1999)

The college solution: a guide for everyone looking for the right school at the right price
por: O'Shaughnessy, Lynn
Publicado: (2008)

The truth about maximizing college 529 accounts
por: O'Shaughnessy, Lynn
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ab9v74001do6e53g4ok68f1tov